Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Coya Therapeutics, Inc. has received a consensus rating of "Buy" from five analysts, with an average twelve-month price target of $16.20.
• The company's stock price recently reached $5.72, with a 12-month range between $4.65 and $10.24.
• In the last earnings report, Coya Therapeutics missed expectations with a reported EPS of ($0.36) against a consensus estimate of ($0.22).

Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) has been assigned a consensus rating of "Buy" from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $16.20.

A number of brokerages recently weighed in on COYA. Lake Street Capital began coverage on shares of Coya Therapeutics in a research report on Wednesday, July 9th. They issued a "buy" rating and a $16.00 price target on the stock. BTIG Research restated a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a report on Tuesday. Chardan Capital restated a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a report on Wednesday, September 17th. HC Wainwright restated a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday, August 25th. Finally, D. Boral Capital restated a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a report on Monday.

Coya Therapeutics Stock Up 1.0%

NASDAQ:COYA traded up $0.06 during mid-day trading on Tuesday, reaching $5.72. 1,857 shares of the company were exchanged, compared to its average volume of 77,597. Coya Therapeutics has a 12 month low of $4.65 and a 12 month high of $10.24. The company has a fifty day moving average of $6.13 and a 200 day moving average of $5.98. The stock has a market cap of $95.58 million, a PE ratio of -4.61 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million. On average, equities research analysts anticipate that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in COYA. Dauntless Investment Group LLC bought a new position in Coya Therapeutics during the first quarter worth $1,083,000. CM Management LLC boosted its position in shares of Coya Therapeutics by 25.0% in the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after acquiring an additional 40,000 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics in the second quarter valued at about $119,000. Jane Street Group LLC raised its stake in Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after purchasing an additional 13,176 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Coya Therapeutics in the first quarter valued at about $65,000. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.